A Phase 4 interventional study of Influenza vaccination in Myocardial Infarction, Decompensated Chronic Heart Failure and Acute Heart Failure (AHF), sponsored by Wroclaw Medical University. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Wroclaw Medical University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Myocardial Infarction with a site in Poland — 17 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Poland.
Among the 89 studies in Myocardial Infarction with a site in Poland, this one is the 47th largest by planned enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2025, is one of 13 in phase 4, reaches primary completion later than 3 of the 19 other live ones, and was the 87th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →17 of the 89 studies in Myocardial Infarction with a site in Poland are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Poland, Ireland, Latvia and 2 more countries
Ages 18+
Abcentra · Sites in Poland, United States, Czechia and 6 more countries
Ages 18+
Wroclaw Medical University · Sites in Poland
Ages 18+
MEDICOVER SP Z O.O. · Sites in Poland
Ages 18–85
CSL Behring · Sites in Poland, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 30 · Phase 4 13
First in 2002; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 1,012 across the 77 interventional studies, 490 across the 12 observational. Of the 66 that completed or were terminated, 29 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 89 have an industry lead sponsor. The 10 most frequent:
Wroclaw Medical University is the lead sponsor of 99 studies on the registry; 29 are open to participants now.
Wroclaw Medical University has 3 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
9 of the studies in Myocardial Infarction with a site in Poland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT07203846Collegium Medicum w BydgoszczyModulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor | 2026-12-31 |
| NCT06956807ViscofanSafety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells | 2026-12-31 |
| NCT07617376Wroclaw Medical UniversityPre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 89 studies in Myocardial Infarction with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients hospitalized for acute cardiac conditions-including acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies-represent a heterogeneous population at very high risk of recurrent cardiovascular events. Influenza infection may act as a trigger for adverse cardiovascular events. Given the persistently low influenza vaccination uptake despite evidence-based benefits observed in vulnerable populations, including patients with cardiac conditions, new strategies to improve vaccination coverage are being explored. Recently, increasing attention has been directed toward an approach already used in fields such as neonatology, where vaccinations are administered prior to hospital discharge.
In this investigator-initiated, single-center, randomized, open-label interventional study, we will evaluate whether influenza vaccination administered within 24 hours before hospital discharge in patients hospitalized for acute cardiac conditions is safe and effective in reducing subsequent infections, cardiovascular events, and mortality during the 6 months following hospitalization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
standard of care (SOC), including recommendation for influenza vaccination in primary care
pre-discharge influenza vaccine administration
Biological: Influenza vaccination
Influenza vaccination pre-discharge in patients hospitalized for acute cardiac conditions
infection, unplanned cardiovascular hospitalization or cardiovascular death
For the purposes of the study, infection was defined as an acute illness characterized by at least one of the following symptoms or events: * typical symptoms (malaise, fatigue, etc.), * self-measured body temperature of 38°C or higher, * the need for antipyretic / analgesic medication, * medical consultation (e.g. with general practitioner) due to infection, * unplanned hospitalization due to infection.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.
Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 13 months is below that.
Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wroclaw Medical University